SequelSEC

VitaNova Life Sciences Corp VNOV

Wholesale-Apparel, Piece Goods & Notions · CIK 0001699709 · Fiscal year ends 0430

Revenue
$3.03M
Fiscal year ended 2026-04-30
Operating income
$3.60K
Fiscal year ended 2026-04-30
Free cash flow
Unavailable
Fiscal year ended 2026-04-30

VitaNova Life Sciences Corp (VNOV) reported revenue of $3.03M and net income of -$37.30K for the fiscal year ended 2026-04-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from VitaNova Life Sciences Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Wholesale-Apparel, Piece Goods & Notions.

Income

VitaNova Life Sciences Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-302019-04-302018-04-302017-01-25
Revenue$3.03M$2.66M$570.69K$38.00K$120.00K$0$0$0$0$0
Cost of revenue$2.11M$1.09M$192.98K$0UnavailableUnavailableUnavailable$0$0$0
Gross profit$910.59K$1.58M$377.71K$38.00KUnavailableUnavailableUnavailable$0$0$0
Operating income$3.60K$1.21M$205.63K-$24.23K-$13.37K-$52.09K-$72.33K-$71.81K-$48.65KUnavailable
Net income-$37.30K$850.75K$140.86K-$24.23K$139.68K-$52.09K-$72.33K-$106.17K-$1.60K-$7.18K
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesUnavailableshares 25.01Mshares 10.64Mshares 5.87Mshares 5.87Mshares 5.87MUnavailableUnavailableshares 4.84Mshares 3.50M
Pretax income$6.58K$1.20M$205.73K-$24.23K$139.68K-$52.09K-$72.33K-$71.81KUnavailableUnavailable
Income tax expense$43.88K$353.56K$64.87K$0$0$0$0$0$0Unavailable
Diluted EPSUnavailable$0.03$0.01$0.00$0.02$-0.01UnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$733.80K$158.12K$86.75K$62.23K$133.37K$52.09K$72.33K$71.81K$48.65K$7.18K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

VitaNova Life Sciences Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-302019-04-302018-04-302017-01-25
Cash & equivalentsUnavailableUnavailableUnavailable$8.73K$23.10K$0$0$0$4.42KUnavailable
Total assets$2.45M$2.26M$1.19M$8.73K$23.10K$0$0$0$47.76KUnavailable
Current assets$2.43M$2.26M$1.19M$8.73K$23.10K$0$0$0$4.42KUnavailable
Total liabilities$395.78K$347.57K$136.92K$67.94K$58.09K$174.67K$122.58K$50.24K$5.60KUnavailable
Current liabilities$395.78K$347.57K$136.92K$67.94K$58.09K$174.67K$122.58K$50.24K$0Unavailable
Total equity incl. NCI$2.05M$1.91M$1.06M-$59.22K-$34.99K-$174.67K-$122.58K-$50.24K$42.16KUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$105.61K$44.25K$132.87K$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$726.74K$1.27M$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$208.81K$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

VitaNova Life Sciences Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-302019-04-302018-04-302017-01-25
Operating cash flow$814.41K$192.77K-$375.88K-$18.38K$4.06K-$42.29K-$53.58K-$49.11K-$9.30KUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailable$0$0$0-$33.91KUnavailable
Financing cash flow$0-$3.00K$960.19K$4.00K$19.04K$42.29K$53.58K$44.69K$47.42KUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailable$0$0-$4.42K$4.22KUnavailable
Stock-based compensation$179.40K$2.00K$1.00K$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

VitaNova Life Sciences Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-302019-04-302018-04-302017-01-25
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin30.1%59.2%66.2%100.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin0.1%45.4%36.0%-63.8%-11.1%UnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue5.9%0.1%0.2%0.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio6.14x6.49x8.71x0.13x0.40x0.00x0.00x0.00xUnavailableUnavailable
Revenue YoY growth13.7%366.5%1401.8%-68.3%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net margin-1.2%32.0%24.7%-63.8%116.4%UnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate666.8%29.4%31.5%Unavailable0.0%UnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VNOV in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-09-14View SEC filing
10-K · Filed 2026-07-29View SEC filing
10-Q · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-12-15View SEC filing
10-Q · Filed 2025-09-12View SEC filing
10-K · Filed 2025-07-24View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.